



1-14

Docket No. JBP0430CIP1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Miri Seiberg et al.

Serial No. : 10/659,598 Art Unit: 1654

Filed : September 10, 2003 Examiner:

For : Methods for Treating Skin Conditions

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

July 16, 2004  
(Date of Deposit)

Andrea L. Colby  
(Name of applicant, assignee, or Registered Representative)

Andrea L. Colby  
(Signature)

July 16, 2004  
(Date of Signature)

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This copy is supplemental to the Information Disclosure Statement mailed on February 2, 2004.

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

- Statement in Accordance with §1.97(e)  
(attached); or
- Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee.

Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).

Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a) (2). (The U.S. patents and each U.S. patent application publication listed on the attached Form PTO-1449 are not enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a) (2) (i)).

There are no listed references which are not in the English language.

The relevance of those listed references which are not in the English language is as follows:

English language claims are provided for EP 0476311 A1 from its B1 document, copy of which is also provided.

English language translation is provided for WANG Acta Entomologica Sinica 38(3):272-274 (1995) publication.

Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

Attached are copies of patent applications/patents which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to  
Deposit Account No. 10-0750/JBP430CIP/ALC. This form is  
submitted in triplicate.

Respectfully submitted,

Andrea L. Colby  
Andrea L. Colby  
Reg. No. 30,194  
Attorney for Applicants

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(732) 524-2792

DATED: *July 16, 2004*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

Application Number

10/659,598

Filing Date

September 10, 2003

First Named Inventor

Miri Seiberg

Group Art Unit

1654

Examiner Name

Attorney Docket Number

JBP0430CIP1

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	KindCode <sup>5</sup>				
		EP	0 341 745	A1	FIDIA S.p.A.	11-15-1989		
		EP	0 476 311	A1	De Stoutz	03-25-1992	English Claims from B1 document	No

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
/SG/		BABIARZ-MAGEE ET AL, "The Expression and Activation of Protease-Activated Receptor-2 Correlate with Skin Color", <i>Pigment Cell Res</i> , Vol. 17 (2004) pp 241-251.	
		HERMANN ET AL, "Unraveling the Patterns of Subclinical Pheomelanin-Enriched Facial Hyperpigmentation: Effect of Depigmenting Agents", <i>Dermatology</i> , Vol. 201 (2000) pp 118-122.	
		LIU ET AL, "Application of Soy in Skin Care", <i>Journal Nutr.</i> , Vol. 132 (2002) pp 574S.	
		PAIN ET AL, "An Alternative Approach to Depigmentation by Soybean Extracts via Inhibition of the PAR-2 Pathway", <i>Journal Investigative Dermatology</i> , Vol. 116 (2001) pp 587-595.	
		SCOTT ET AL, "Protease-Activated Receptor 2, a Receptor Involved in Melanosome Transfer, is Upregulated in Human Skin by Ultraviolet Irradiation", <i>Journal Investigative Dermatology</i> , Vol. 117 (2001) pp 1412-1420.	
		SCOTT ET AL, "Proteinase-Activated Receptor-2 Stimulates Prostaglandin Production in Keratinocytes: Analysis of Prostaglandin Receptors on Human Melanocytes and Effects of PGE2 and PGF2 $\alpha$ on Melanocyte Dendricity", <i>Journal Investigative Dermatology</i> , Vol. 122 (2004) pp 1214-1224.	
		SCOTT ET AL, "The Proteinase-Activated Receptor-2 Mediates Phagocytosis in a Photo-Dependent Manner in Human Keratinocytes", <i>Journal Investigative Dermatology</i> , Vol. 121 (2003) pp 529-541.	
		SEIBERG ET AL, "Inhibition of Melanosome Transfer Results in Skin Lightening", <i>Journal Investigative Dermatology</i> , Vol. 115 (2000) pp 162-167.	
		SEIBERG ET AL, "Soy Extracts Reduce Hair Growth and Hair Follicle Dimensions", <i>Hair Science and Technology</i> , D. Van Neste (editor) (2003) pp 391-400.	
		SEIBERG ET AL, "Soymilk Reduces Hair Growth and Hair Follicle Dimensions", <i>Experimental Dermatology</i> , Vol. 10 (2001) pp 405-423.	
		SEIBERG ET AL, "The Protease-Activated Receptor 2 Regulates Pigmentation via Keratinocyte-Melanocyte Interactions", <i>Experimental Cell Research</i> , Vol. 254 (2000) pp 25-32.	
		SEIBERG ET AL, "The Protease-Activated Receptor-2 Regulates Pigmentation via Melanosome Phagocytosis", <i>Mechanisms of Suntanning</i> , J. P. Ortonne and R. Ballotti (editors) (2002) pp 215-278.	
		SEIBERG ET AL, "The Regulation of Pigmentation by Serine Proteases and Their Inhibitors", <i>Inhibition of Human Proteases: From Target Identification to Therapy</i> , CHI Press (1998) pp 1-3.	
		SEIBERG, "Keratinocyte-Melanocyte Interactions During Melanosome Transfer", <i>Pigment Cell Res.</i> , Vol. 14 (2001) pp 236-242.	
		SHARLOW ET AL, "The Protease-Activated Receptor-2 Upregulates Keratinocyte Phagocytosis", <i>Journal of Cell Science</i> , Vol. 113 (2000) pp 3093-3101.	
		WANG ET AL, "Effects of Soybean Trypsin Inhibitor on Digestive Physiology and Growth and Development of <i>Helicoverpa Armigera</i> Larvae", <i>Acta Entomologica Sinica</i> , Vol. 38, No. 3 (August 1995) pp 272-274.	Yes
/SG/		WILSON ET AL, "Immunocytochemical Study of the Interaction of Soybean Trypsin Inhibitor with Rat Intestinal Mucosa", <i>Gut</i> , Vol. 19 (1978) pp 260-266.	

Examiner Signature	/ Shirley Gembeh/	Date Considered	8/19/11
--------------------	-------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450